Incidence and Prognostic Significance of Immunophenotypic Subgroups in Childhood Acute Lymphoblastic Leukemia: Experience of the BFM Study 86

Wd, Ludwig; Harbott, Jochen; Bartram, CR; Komischke, B.; Sperling, Christian; Teichmann, J. V.; Seibt-Jung, H.; Notter, Michael; Odenwald, E.; Nehmer, A.; Thiel, Eckhard; Riehm, H.

doi:10.1007/978-3-642-84895-7_24

Cited by 52 publications

(40 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…22,23 The vast majority of T-ALL cases also express the CD7 antigen. [2][3][4]24 Based on these observations, we have focused our studies on T cell subsets in the CD7 + lymphoid population of normal BM. We have a Results are expressed as numbers of cases and percentages.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3] Most T-ALL cases display phenotypes corresponding to various stages of thymocyte differentiation, which normally are not found in bone marrow (BM) or peripheral blood (PB). 4 The aberrant immunophenotypic characteristics of leukemic T lymphoblasts allow discrimination from T cell subsets in BM and thus can be used for detection of minimal residual disease (MRD).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL)

et al. 2000

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL)

et al. 2000

View full text Add to dashboard Cite

“…The Ludwig system is based on the expression of CD1 and CD3, in CD7 and cy CD3-positive patients. 33 Interestingly, Pui et al's 37 results showed that SJCRH patients with leukemic cell expression of surface CD3, corresponding to a mature stage phenotype, had a significantly poorer treatment outcome than did cases with blasts lacking the CD3 antigen. This is similar to our results showing adverse outcome for the mature (CD1-negative, CD3-positive) subgroup.…”

Section: Figurementioning

confidence: 99%

“…T-ALL maturational stage was defined according to a modification of the Ludwig T-ALL maturational staging definitions 33 as follows: early stage (CD1 negative, CD3 negative); intermediate stage (CD1 positive, CD3 negative or positive); and mature stage (CD1 negative, CD3 positive). These modifications were made because only a few of our patient samples had been tested for cytoplasmic CD3.…”

Section: Definitionsmentioning

confidence: 99%

“…However, after Ludwig et al 33 described their staging system and showed a significant difference in outcome among early, intermediate, and mature subgroups, we decided to employ a modified Ludwig system for our patients. Using this modified Ludwig maturational staging system, we were able to categorize every patient with T-ALL who had satisfactory immunophenotyping.…”

Section: Figurementioning

confidence: 99%

See 1 more Smart Citation

True

1999

Leukemia

View full text Add to dashboard Cite

Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) studyT cell acute lymphocytic leukemia (T-ALL) and B-precursor ALL differ significantly in the clinical characteristics of the patients at presentation and in laboratory-defined characteristics of the leukemic cells. We assessed for pediatric patients with T-ALL the relative importance of prognostic factors previously demonstrated to predict outcome in B-precursor ALL. Presenting clinical and laboratory features were correlated with outcome for 441 children 12 months to 21 years of age with previously untreated T-ALL, registered on the Pediatric Oncology Group (POG) T3 protocol between 1986 and 1992. These T-ALL prognostic factor analyses were then compared to similar analyses for 1993 patients with B-precursor ALL enrolled during the same time period on the POG ALinC 14 protocol. Quantitative interaction between phenotype and each prognostic factor was studied to determine the relative importance of the prognostic factor for each of the two major immunophenotypes. We also analyzed the importance of maturational stage as a T-ALL prognostic factor, using a modified Ludwig definition of maturational stage. We conclude that several of the clinical and laboratory prognostic factors, which are used reliably for Bprecursor ALL, are much less predictive in T-ALL (ie age, WBC, consensus risk group, hyperdiploidy, presence of translocations and CALLA expression). There was no significant difference between the phenotypes in the prognostic importance of race or gender. Our data demonstrate a significant difference in outcome among the three maturational stages of Tcell ALL, with the intermediate group faring best. Using traditional risk group criteria to stratify patients with T-ALL for therapy may not be appropriate.

show abstract